1. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N Engl J Med 1996;335:609-616.

2. Akimoto K, Hamamura T, Kazahaya Y, Akijama K, Otsuki S. Sub-chronic cocaine treatment enhances cocaine induced dopamine efflux studies by in vivo intracerebral dialysis. Brain Res 1989;490:339-334.

3. Alexander GE, Crutcher MD. Functional architects of the basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.

4. Ali SF, Newport GD, Holson RR, Slikker W, Bowyer JF. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res 1994;658:33-38.

5. Allgaier C, Feuerstein TJ, Hertting G. N-Ethylmaleimide (NEM) diminishes alpha2-adrenoceptor mediated effects on noradrenaline release. Naunyn-Schmiedebergs Arch Pharmacol 1986;33:104-109.

6. Anggard E, Jonsson LE, Hogmark AL, Gunne LM. Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 1973;14:870-880.

7. Angrist B. Amphetamine psychosis: clinical variations of the syndrome. In: Cho AK, Segal DS, eds. Amphetamine and its analogs. New York: Academic Press 1995;387-411.

8. Angrist B, D'Hollosy M, Sanfilipo M, et al. Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment. J Clin Psychopharmacol 1992;12:268-272.

9. Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: Behavioral and biochemical aspects. J Psychiatr Res 1974;11:13-23.

10. Angrist B, Gershon S. Amphetamine abuse in New York City—1966 to 1968. Sem Psychiatry 1969;1:195-207.

11. Axt KJ, Molliver ME. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse 1991;9:302-313.

12. Ayd FJ, Zohar J. Psychostimulant (amphetamine or methylphenidate) therapy for chronic and treatment-resistant depression. In: Zohar J, Bellmaker RH, eds. Treating resistant depression. New York: PMA Publishing Corp, 1987;343-355.

13. Balster RL, Schuster CR. A comparison of d-amphetamine, l-amphetamine and methamphetamine self-administration in rhesus monkeys. Pharmacol Biochem Behav 1973;1:67-71.

14. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 1977;18:137-165.

15. Bartlett E, Hallin A, Chapman B, Angrist B. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability. Neuropsychopharmacology 1977;16:77-82.

16. Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 1973;197329:35-40.

17. Bellmaker RH, Wald D. Haloperidol in normals. Br J Psychiatry 1977;131:222-223.

18. Bennett IL, Walker WE. Cardiac arrhythmias following the use of large doses of central nervous system stimulants. Am Heart J 1952;44:428.

19. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:1792-1798.

20. Bleuler E. Textbook of psychiatry. New York: McMillan, 1924.

21. Bowyer JF, Davies DL, Schmued L, et al. Further studies in the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994;268:1571-1580.

22. Bracha HS. Is there a right hemi-hyper-dopaminergic psychosis. Schizophr Res 1989;2:317-324.

23. Brady KT, Lydiard RB, Malcolm RB, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991;52:509-512.

24. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993;70:537-541.

25. Brill H, Hirose T. The rise and fall of the methamphetamine epidemic in Japan, 1945-1955. Sem Psychiatry 1969;19731:179-194.

26. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med 1988;18:49-55.

27a. Cameron DL, Williams JT. Dopamine D1 receptors facilitate transmitter release. Nature. 1993;336:334-347.

27. Castellani, S, Petrie, WM, Ellinwood EH, Jr. Drug-induced psychosis: neurobiological mechanisms. In: Alterman AI, ed. Substance abuse and psychopathology. New York: Plenum Press, 1985;173-210.

28. Castenata B, Becker JB, Robinson TE. The long-term effects of repeated amphetamine treatment in vivo on amphetamine KCl and electrical stimulation evoked striatal dopamine release in vitro. Life Sci 1988;42:2447-2456.

29. Caldwell L. The psychological action of cuca and cocaine. Br Med J 1885;1:17pp.

30. Chen N, Reith MA. Dopamine and serotonin release—regulating autoreceptor sensitivity in A9 /A10 cell body and terminal after withdrawal from continuous infusion of cocaine. J Pharmacol Exp Ther 1993;267:1445-1453.

31. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 1987;44:286-295.

32. Connell PH. Amphetamine psychosis. In: Maudsley Monographs No. 5. London: Oxford University Press, 1958.

33. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.

34. Costall B, Naylor RJ, Olley JE. Stereotypic and anticataleptic activities of amphetamine after intracerebral injections. Eur J Pharmacol 1972;18:83-94.

35. Crouch DJ, Birky MM, Gust SW, et al. The prevalence of drugs and alcohol in fatally injured truck drivers. J Forensic Sci 1993;38:1342-1353.

36. Cubellis JF, Rauport S, Rajendran G, Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 1994;14:2260-2271.

37. Denny-Brown D, Yanizawa N. The role of the basal ganglia in the initiation of movement. In: Yahr MD, ed. The basal ganglia. Res Publ Assoc Nerv Ment Dis 1976;55:115-148.

38. Devenport LD, Devenport JA, Holloway FA. Stereotypy: Modulation by the hippocampus. Science 1981;212:1288-1289.

39. Dougherty, GG, Ellinwood EH, Jr. Amphetamine behavioral toxicity: rotational behavior after chronic intrastriatal infusion. Biol Psychiatry 1981;16:479-488.

40. Dougherty GG, Ellinwood EH, Jr. Chronic d-amphetamine in nucleus accumbens: lack of tolerance or reverse tolerance of locomotor activity. Life Sci 1981;28:2295-2298.

41. Downs AW, Eddy MB. The effect of repeated doses of cocaine in the rat. J Pharmacol Exp Ther 1931;46:199.

42. Duarte-Escalante O, Ellinwood EH, Jr. Central nervous system cytopathological changes in cat with chronic methedrine intoxication. Brain Res 1970;21:151-155.

43. Dwoskin LP, Peris J, Yashuda RP, Philpott K, Zahniser NR. Repeated cocaine administration results in supersensitivity of striatal D2 autoreceptors to pergolide. Life Sci 1980;42:255-262.

44. D'haenen HA, Bossuyt A. Dopamine D2 receptor density in depression measured with single photon emission computed tomography. Biol Psychiatry 1994;35:128-132.

45. Edwards G, Arif A, Hodgson R. Nomenclature and classification of drug- and alcohol-related problems: a WHO memorandum. Bull WHO 1981;59:225-242.

46. Ellinwood EH, Jr, Lee TH. Central nervous system stimulants and anorectic agents. In: Dukes MNG, ed. Meyler's side effects of drugs, 13th Edition. New York: Elsevier Biomedical Publishers, 1996;1-30.

47. Ellinwood EH, Jr, Lee T. Effect of continuous systemic infusion of d-amphetamine on the sensitivity of nigral dopamine cells to apomorphine inhibition of firing rates. Brain Res 1983;273:379-383.

48. Ellinwood EH, Jr, Kilbey, MM. Chronic stimulant intoxication models of psychosis. In: Hanin I, Usdin E, eds. Animal models in psychiatry and neurology. New York: Pergamon Press, 1977;61-74.

49. Ellinwood EH, Jr, Petrie WM. Dependence on amphetamine, cocaine and other stimulants. In Pradham SN, ed. Drug abuse: Clinical and basic aspects. pp. 248-262. New York: C.V. Mosby Publishing Company, 1977.

50. Ellinwood EH, Jr, Kilbey MM. Amphetamine stereotypy: the influence of environmental factors and prepotent behavioral patterns on its topography and development. Biol Psychiatry 1975;10:3-16.

51. Ellinwood EH, Jr, Sudilovsky A, Nelson L. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry 1973;130:1088-1093.

52. Ellinwood EH, Jr. Amphetamine and stimulant drugs. In: Drug Use in America: Problem in Perspective. Vol. I. Second report of the National Commission on Marijuana and Drug Abuse. Wash. DC: U.S. Gov't. Printing Office, 1973;140-157.

53. Ellinwood EH, Jr, Sudilovsky A. Chronic amphetamine intoxication: behavioral model of psychoses. In: Cole J, et al. eds. Psychopathology and psychopharmacology. Baltimore: John Hopkins University Press, 1973;51-70.

54. Ellinwood EH, Jr, Duarte-Escalante O. Chronic methamphetamine intoxication in three species of experimental animals. In: Ellinwood EH, Jr, Cohen S, eds. Current concepts on amphetamine abuse. Washington, DC: U.S. Gov't. Printing Office, 1972;59-68.

55. Ellinwood EH, Jr, Sudilovsky A, Nelson L. Behavioral analysis of chronic amphetamine intoxication. Biol Psychiatry 1972;4:215-229.

56. Ellinwood EH, Jr. Amphetamine psychosis: individuals, settings, and sequences. In: Ellinwood EH, Jr, Cohen S, eds. Current concepts on amphetamine abuse. Washington, DC: U.S. Gov't. Printing Office, 1972b;143-157.

57. Ellinwood EH, Jr. "Accidental conditioning" with chronic methamphetamine intoxication: implications for a theory of drug habituation. Psychopharmacologia 1971;21:133-138.

58. Ellinwood EH, Jr. Assault and homicide associated with amphetamine abuse. Am J Psychiatry 1971;127:1170-1175.

59. Ellinwood EH, Jr. Amphetamine psychosis. II. Theoretical implications. Int. Neuropsychiatry 1968;4:45-54.

60. Ellinwood EH, Jr. Amphetamine Psychosis. I. Description of the individuals and processes. J Nerv Ment Dis 1967;144:273-283.

61. Ellison GD. Paranoid psychosis following continuous amphetamine or cocaine: relationship to selective neurotoxicity. In: Korenman SG, Barchas JD, eds. Biological basis of substance abuse. New York: Oxford University Press, 1993;355-371.

62. Ellison G. Continuous amphetamine and cocaine have similar neurotoxic effects in the lateral habenular nucleus fasciculus retroflexus. Brain Res 1992;598:353-356.

63. Ellison GD, Eison MA. Continuous amphetamine intoxication: an animal model of the acute psychotic episode. Psychol Med 1983;13:751-762.

64. Ellison G, Eison MS, Huberman HS, Daniel F. Long-term changes in dopaminergic intervention of the caudate nucleus after continuous amphetamine administration. Science 1978;201:276-278.

65. Fiddle S. Circles beyond the circumference: some hunches about amphetamine abuse. In: Russo JR, ed. Amphetamine abuse. Charles Thomas Publisher, 1968;66-87.

66. Fischer JF, Cho AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 1979;192:642-653.

67. Fitzgerald LW, Nestler EJ. Cocaine regulation of signal transduction pathways. In: Hammer R, ed. The neurobiology of cocaine. CRC Press. 1995;225-246.

68. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 1997;282:834-838.

69. Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat 1996;13:493-497.

70. Gawin GH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989;46:117-121.

71. Gawin FH, Khalsa-Denison ME. Is craving mood driven or self-propelled? Sensitization and "street" stimulant addiction. NIDA Res Monogr 1996;163:224-250.

72. Gawin FH, Khalsa ME, Ellinwood EH. Stimulants. In: Galanter M, Kleber HD, eds. Textbook of substance abuse treatment. Washington, DC: American Psychiatric Association Press, 1994;111-139.

73. Gawin FH. Cocaine addiction: Psychology and neurophysiology. Science 1991;251:1580-1586.

74. Gawin FH, Ellinwood EH. Cocaine and other stimulants. N Engl J Med 1988;318:1173-1182.

75. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations. Arch Gen Psychiatry 1986;43:107-113.

76. Gay G, Inaba D, Sheppard C, Newmeyer J, Rappolt R. Cocaine: history, epidemiology, human pharmacology and treatment. Clin Toxicol 1975;8:149-178.

77. Gessell A. The embryology of behavior: The beginnings of the human mind. New York: Harper, 1945.

78. Geyer MA, Markou A. Animal models of psychiatric disorders: Psychopharmacology. In: Bloom F, Kupfer D, eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press 1995;787-798.

79. Glick SD, Greenstein S. Possible modulating influence of frontal cortex on nigro-striatal function. Br J Pharmacol 1973;49:316-321.

80. Goodwin FK, Evert MH, Bunney WE. Mental effects of reserpine in man: a review. In: Shader RI, ed. Psychiatric complications of medical drugs. New York: Raven Press, 1972;73-101.

81. Gotestam KG, Gunne L. Subjective effects of two anorexigenic agents, fenfluramine and AN488, in amphetamine-dependent subjects. Br J Addict 1972;197367:39-44.

82. Grant S, London ED, Newlin DB, et al. Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci USA 1966;93:12040-12045.

83. Graybiel AM, Kimura M. Adaptive neural networks in the basal ganglia. In: Houk JC, Davis JL, Beiser DG, eds. Models of information processing in the basal ganglia. Cambridge, MA: MIT Press, 1995;103-116.

84. Green AL, El Hait AS. A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline. Biochem Pharmacol 1980;29:2781-2789.

85. Greenblatt JC, Gfroerer JC. Methamphetamine abuse in the United States. Office of Applied Studies, Substance Abuse and Mental Health Administration, 1996.

86. Griffith JD. A study of illicit amphetamine drug traffic in Oklahoma City. Am J Psychiatry 1966;123:560-569.

87. Groves PM, Garcia-Munoz M, Linder JC, Manley MS, Martone ME, Young SJ. Elements of the intrinsic organization and information processing in the neostriatum. In: Houk JC, Davis JL, Beiser DG, eds. Models of information processing in the basal ganglia. MIT Press: Cambridge, MA, 1995;51-100.

88. Groves PM. A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement. Brain Res Rev 1983;5:109-132.

89. Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW and Hanson GR. Mechanisms for tolerance to methamphetamine effects. Neuropharmacology 1996;35:751-757.

90. Hechtman L. Adolescent outcome of hyperactive children treated with stimulants in childhood. A review. Psychopharmacol Bull 1985;21:178-191.

91. Herdon H. N-Ethylmaleimide inactivates adenylate cyclase-coupled but not presynaptic striatal D-2 receptor systems. Eur J Pharmacol 1988;154:115-116.

92. Holmes HF, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry 1989;50:5-8.

93. Horita A, Quock RM. Dopaminergic mechanisms in drug-induced temperature effects. In: Temperature regulation and drug action. Paris: Karger, 1974;75-84.

94. Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ Health Prospect 1984;55:53-76.

95. Iversen SD, Koob GF. Behavioral implications of dopaminergic neurons in the mesolimbic system. Adv Biochem Psychopharmacol 1977;16:209-214.

96. Iversen SD. The effect of surgical lesions to frontal cortex and substantia nigra on amphetamine response in rats. Brain Res 1971;31:295-311.

97. Iwanami A, Kanamori R, Suga I, Kaneko T, Kinijima K. Reduced attention-related negative potentials in methamphetamine psychosis. J Nerv Ment Dis 1995;183:693-697.

98. Izenwasser S, Cox BM. Inhibition of dopamine uptake by cocaine and nicotine: tolerance to chronic treatments. Brain Res 1992;573:119.

99. Jackson S, Houghton G. Sensorimotor selection and the basal ganglia: a neural network model. In: Houk JC, Davis JL, Beiser DG, eds. Models of information processing in the basal ganglia. Cambridge, MA:, MIT Press, 1995;337-367??.

100. Jaffe JH. Amphetamine (or amphetamine-like)-related disorders. In: Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry. Baltimore: Williams and Wilkins, 1995;791-799.

101. Jaffe JH. Drug addiction and drug abuse. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. New York, NY: Macmillan, 1990;522-573.

102. Jaffe JH. Drug addiction and drug abuse. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. New York, NY: Macmillan, 1980;535-584.

103. Jaffe JH. Drug addiction and drug abuse. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. New York, NY: Macmillan, 1975;284-324.

104. Janowsky DS, El-Yousef MK, Davis JM, Sejerke HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973;28:185-191.

105. Jellinek EM. The disease concept of alcoholism. New Haven, CT: Hillhouse Press, 1960.

106. Jones SR, Lee TH, Wightman RM, Ellinwood EH. Effects of intermittent and continuous cocaine administration on dopamine release and uptake regulation in the striatum: in vitro voltametric assessment. Psychopharmacology 1996;126:331-338.

107. Jones RT. The pharmacology of cocaine. NIDA Res Monogr 1984;50:34-53.

108. Kalant OJ. The amphetamines: Toxicity and addiction. Springfield, Ill: Charles C Thomas, 1966.

109. Kalivas PW, Duffy P. The effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse 1990;5:48-58.

110.a Kalivas PW, Stewart J. Popamine transmission in the initiation and expression of arigand stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991;16:223-244.

110. Kalivas PW, Weber B. Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine. J Pharmacol Exp Ther 1988;245:1095-1102.

111. Kilbey MM, Ellinwood EH, Jr. Reverse tolerance to stimulant-induced abnormal behavior. Life Sci 1977;20:1063-1076.

112. Kilbey MM, Ellinwood EH, Jr. The effect of age-related factors on behavior induced by cocaine. Life Sci 1977;20:1847-1854.

113. Kimura M, Aosaki T, Ishida A. Neuropsychological aspects of the differential roles of the putamen and caudate nucleus in voluntary movement. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Parkinson's disease. From basic research to treatment. New York: Raven Press, 1993;62-70.

114. King GR, Silvia C, Joyner CM, et al. Withdrawal from continuous or intermittent cocaine administration: changes in D2 receptor functioning. J Pharmacol Exper Ther 1994;269:743-749.

115. King GR, Joyner C, Lee T, Kuhn C, Ellinwood EH, Jr. Intermittent and continuous cocaine administration: Residual behavioral states during withdrawal. Pharmacol Biochem Behav 1992;43:243-248.

116. King GR, Ellinwood EH. Amphetamines and other stimulants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: A comprehensive textbook. 3rd Ed, Philadelphia: Williams and Wilkins, 1997;207-223.

117. Klawans HL, Crossett P, Dana N. Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of L-dopa-induced dyskinesias. Adv Neurol 1975;9:105-112.

118. Klawans HL. The pharmacology of extrapyramidal movement disorders. Basel: Karger, 1973.

119. Kleven MS, Woolverton WL, Seiden LS. Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. Brain Res Bull 1988;21:233-237.

120. Klein DF. Depression and anhedonia. In: Clark DC, Fawcett J, eds. Anhedonia and affect deficit states. New York: PMA Publishers, 1987;1-14.

121. Kokkinidis L, McCarter BD. Post cocaine depression and sensitization of brain stimulation reward. Pharmacol Biochem Behav 1990;36:463-471.

122. Kokkinidis L, Zacharko RM, Predy PA. Post-amphetamine depression of self-stimulation responding from the substantia nigra: reversal by tricyclic antidepressants. Pharmacol Biochem Behav 1980;13:379-383.

123. Kolta MG, Shreve P, DeSouza V, Uretsky NJ. Time course of the development of enhanced behavioral and biochemical responses to amphetamine after treatment with amphetamine. Neuropharmacology 1985;24:823-826.

124. Konradi C, Cole RL, Heckers S, Hyman SE. Amphetamine regulation in expression in the rat striatum via transcription factor CREB. J Neurosci 1994;14:563.

125. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715,723.

126. Kramer JC, Fischman VS, Littlefield DC. Amphetamine abuse: pattern and effects of high doses taken intravenously. JAMA 1967;201:305-309.

127. Kuczenski R, Segal DS. Neurochemistry of amphetamine. In: Cho AK, Segal DS, eds. Amphetamine and its analogs: Psychopharmacology, toxicology, and abuse. New York: Academic Press, 1994;81-114.

128. La Rue A. Aging and neuropsychological assessment. New York: Plenum, 1992.

129. Lee T, Ellinwood EH, Jr. Time-dependent changes in the sensitivity of dopamine neurons to low doses of apomorphine following amphetamine infusion: electrophysiological and biochemical studies. Brain Res 1989;483:17-29.

130. Lee TH, Ellinwood EH, Nishita JK, Hoffman GW. Does hyperthermia decrease negative feedback in nigrostriatal dopaminergic neurons? Pharmacol Toxicol 1988;62:344-345.

131. Levin BE, Tomer R, Rey GJ. Cognitive impairment in Parkinson's disease. Neurologic Clin 1992;10:471-485.

132. Lidsky TI. Neuropsychiatric implications of basal ganglia dysfunction. Biol Psychiatry 1997;41:383-385.

133. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990;16:97-110.

134. Looney J. Substance abuse in adolescents: diagnostic issues derived from studies of attention deficit disorder with hyperactivity. NIDA Res Monogr 1988;77:19-26.

135. Lüllmann H, Lüllman-Rauch R, Wassermann O. Drug-induced phospholipidosis. CRC Crit Rev Toxicol 1975;4:185-218.

136. Lund, Preusser, Williams. Drug use by tractor-trailer drivers. NIDA Res Monogr 1989;91:47-67.

137. Lyon M, Robbins T. The action of central nervous system stimulant drugs: A general theory concerning amphetamine effects. Curr Dev Psychopharmacol 1975;2:80-163.

138. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom F, Kupfer D, eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press, 1995;933-944.

139. Malberg JE, Sabol KE, Seiden LS. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 1996;278:258-268.

140. Markou A, Weiss F, Gold LH, Caine SB, Schilteis G, Koob GF. Animal models of drug craving. Psychopharmacology 1993;112:163-182.

141. Marlatt GA. Craving notes. Br J Addict 1987;92:42-43.

142. Mattay VS, Berman KF, Ostrem JL, Esposito G, VanHorn JV, Bigelow LV, Weinberger DR. Dextroamphetamine enhances "neural network specific" physiological signals: a positron-emission tomography rCBF study. J Neurosci 1996;16:4816-4822.

143. McPherson S, Cummings J.L. Neuropsychological aspects of Parkinson's disease and parkinsonism. In: Grant I, Adams KM, eds. Neuropsychological assessment of neuropsychiatric disorders. New York: Oxford University Press, 1996;288-311.

144. Medical memorandum. Amphetamine overdosage in an athlete. Br Med J 1960;2:590-.

145. Melega WP, Williams AE, Schmitz DA, DiStefano EW and Cho AK Pharmacokinetic and pharmacodynamic analysis of the actions of d-amphetamine and d-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 1995;274:90-96.

146. Mesulain MM, Geschwind N. The nature of schizophrenia. New York: Wiley Publishing, 1978.

147. Middleton FA, Strick PL. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science 1994;266:458-461.

148. Miller HH, Shore PA, Clarke DE. In vivo monoamine oxidase inhibition by d-amphetamine. Biochem Pharmacol 1980;29:1347-1354.

149. Mitler MN, Erman N, Hajdukovic R. Treatment of excessive somnolence with stimulant drugs. Sleep 1993;16:203-206.

150. Muscat R, Patel J, Trout SJ, Wieczorek W, Kruk ZL. Association of the effects of amphetamine and quinpirole on dopamine release in the nucleus accumbens following behavioral sensitization: ex vivo voltametric study. Behav Pharmacol 1993;4:411-418.

151. Nakatani Y. Diagnosis and clinical symptomatology of methamphetamine psychosis. Japan-U.S. Scientific symposium ‘90 on drug dependence and abuse, cocaine and methamphetamine behavioral toxicology. Clin Psychiatr Epidemiol Tokyo: Keiran, 1990;333.

152. Nakatani Y, Yoshizawa F, Yamada H, Iwanami A, Sakaguchi M. Methamphetamine psychosis in Japan: a survey. Br J Addict 1989;84:1548-1549.

153. Nausieda PA. Central stimulant toxicity. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology, Vol 37, Intoxications of the nervous system, Part II. Amsterdam: North Holland Publishing Co., 1979;223-297.

154. Nielsen EB, Lee TH, Ellison GD. Following several days of continuous administration d-amphetamine acquired hallucinogen-like properties. Psychopharmacology 1980;68:197-200.

155. Nestler EJ, Terwilliger RZ, Walker JR, Kalivas PW. Chronic cocaine levels decreases levels of the G protein subunits G1 and G0 in discrete regions of rat brain. J Neurochem 1990;55:1079-1082.

156. Nunes EV, McGrath PJ, Quitkin FM, Ocepek-Welikson K, Stewart JW, Koenig T, Wager S, Klein DF. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 1995;39:185-195.

157. Nwanzi E, Jonsson G. Amphetamine neurotoxicity on dopamine nerve terminals in the caudate nucleus of mice. Neurosci Lett 1981;26:163-168.

158. Parsons LH, Smith AD, Justice JB, Jr. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 1991;9:60-65.

159. Paulson PE, Robinson TE. Regional differences in the effects of amphetamine withdrawal on dopamine dynamics in the striatum. Neuropsychopharmacology 1966;14:325-337.

160. Paulson PE, Camp DM, Robinson TE. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 1991;103:480-492.

161. Peat MA, Warren PF, Gibb JW. Effects of single-dose of methamphetamine and iprindole on the serotonergic and dopamine system of the rat brain. J Pharmacol Exp Ther 1983;225:126-131.

162. Pert A. Neurobiological mechanisms underlying the acquisition and expression of incentive motivation by cocaine-associated stimuli: Relationship to craving. NIDA Res Monogr 1994;145:163-190.

163. Pert A, Post RM, Weiss SRB. Conditioning as a critical determinant of sensitization induced by psychomotor stimulants. NIDA Res Monogr 1990;97:208-241.

164. Pijenburg AJJ, van Rossum JM. Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens. J Pharm Pharmacol 1973;25:1003-1005.

165. Post RM, Gerner RH, Carman IS. Effects of a dopamine agonist pinbedil in depressed patients. Arch Gen Psychiatry 1978;35:609-615.

166. Post RM, Kopanda RT. Cocaine, kindling, and reverse tolerance. Lancet 1975;1:409-410.

167. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163:30-34.

168. Raiteri M, Cerrito F, Cervoni A, Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 1979;208:195-202.

169. Randrup A, Munkvad I. Brain dopamine and amphetamine-induced stereotyped behaviour. Acta Pharmacol Toxicol 1967;25(suppl 4):62.

170. Rickels K, Ginrich Rl Jr, Mclaughlin W, et al. Methylphenidate in mildly depressed outpatients. Clin Pharmacol Ther 1972;13:595-601.

171. Rickels K, Gordon PE, Gansman DH, Weise CC, Pereira-Ogan JA, Hesbacher PT. Pemoline and methylphenidate in mildly depressed outpatients. Clin Pharmacol Ther 1970;11:698-710.

172. Ricaurte GA, Seiden LS, Schuster CR. Further evidence that amphetamine produced long lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res 1984;303:358-364.

173. Ridley RM. The psychology of perseverative and stereotyped behavior. Prog Neurobiol 1994;44:221-231.

174. Robbins TW, Sahakian BJ. Behavioral effects of psychomotor stimulant drugs: Clinical and neuropsychological implications. In: Creese I, ed. Stimulants: Neurochemical, behavioral and clinical perspectives. New York: Raven Press, 1983;301-338.

175. Robinson TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev 1993;18:247-292.

176. Robinson TE. Persistent sensitizing effects of drugs on brain dopamine systems and behavior: implications for addiction and relapse. In: Korenman SG, Barchas JD, eds. Biological basis of substance abuse. New York: Oxford University Press, 1993;373-404.

177. Robinson TE, Jurson PA, Bennett JA, Bentgen KM. Persistent sensitization of dopamine transmission in the ventral striatum (nucleus accumbens) produced by prior experience with amphetamine: a microdialysis study in freely moving rats. Brain Res 1988;462:211-222.

178. Ross HE, Swinson R, Dowmani S, Larkin EJ. Diagnosing comorbidity in substance abusers: a comparison of the test-retest reliability of two interviews. Am J Drug Alchohol Abuse 1995;21:167-185.

179. Rosse RB, Fay-McCarthy M, Collins JP, Jr, Alim TN, Deutsch SI. The relationship between cocaine-induced paranoia and compulsive foraging: a preliminary report. Addiction 1994;89:1097-1104.

180. Rounsaville BJ, Anton SF, Carroll K, Buddie D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991;48:43-51.

181. Ryan LJ, Linder JC, Martone ME, Groves PM. Histological and ultrastructural evidence that d-amphetamine causes degeneration in the neostriatum and frontal cortex of rats. Brain Res 1990;518:67-77.

182. Ryan LC, Martoni ME, Linder JC, Groves PN. Cocaine in contrast to d-amphetamine, does not cause accidental terminal degeneration in the neostriatum and agranular frontal cortex of Long-Evans rats. Life Sci 1988;43:1403-1409.

183. Satel SL, Siebyl JP, Charney DS. Prolonged cocaine psychosis implies underlying major psychopathology. J Clin Psychiatry 1991;52:349-350.

184. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989;50:241-249.

185. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patience with previous methamphetamine psychosis. Biol Psychiatry 1983;18:429-440.

186. Schiorring E. Changes in individuals and social behavior induced by amphetamine and related compounds in monkeys and man. In: Ellinwood EH, Kilbey M, eds. Cocaine and other stimulants. New York: Plenum Press, 1977.

187. Schmidt CJ, Gehlert DR, Peat MA, Sonsalla PK, Hanson GR, Wamsley JK and Gibb JW. Studies on the mechanism of tolerance to methamphetamine. Brain Res. 1985;343:305-313.

188. Schultz W, Romo R, Ljungberg T, Mirenowicz J, Hollerman JR, Dickinson A. Reward-related signals carried by dopamine neurons. In: Houk JC, Davis JL, Beiser DG, eds. Models of information processing in the basal ganglia. Cambridge, MA: MIT Press, 1995;233-248.

189. Schultz W. Activity of dopamine neurons in the behaving primate. Semin Neurosci 1992;4:129-138.

190. Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration. In: Bray GA, ed. Obesity in perspective. Washington, DC: DHEW Publication, No. NIH (75-707), 1975;441-443.

191. Segal DS, Kuezenski R. In vivo microdialysis reveals a diminished amphetamine reduced dopamine response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment. Brain Res 1992;571:330-337.

192. Segal DS, Kuezenski R. Repeated cocaine administration induces behavioral sensitization and corresponding decrease extracellular dopamine responses in caudate and accumbens. Brain Res 1992;577:351-355.

193. Segal DA, Mandell AJ. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 1974;2:249-255.

194. Seiden LS, Sabol KE. Methamphetamine methyldioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Mono 1996;163:251-276.

195. Seiden LS, Ricaurte GA. Neurotoxicity of methamphetamine and related drugs. In: Meltzer HY, ed. Psychopharmacology: The third generation of progress. New York: Raven Press, 1987;359-366.

196. Self DW, Barnhart WJ, Lehman DA, Nestler EJ. Opposite modulation of cocaine seeking behavior by D1 and D2-like receptor agonists. Science 1996;271:1586-1589.

197. Silvia CP, Jabert M, King GR, Ellinwood EH, Caron MG. Cocaine and amphetamine elicit differential effects in rats with a unilateral injection of dopamine transporter antisense oligodeoxynucleotides. Neuroscience 1997;76:737-747.

198. Silvia CP, King GR, Lee TH, Xue Z-Y, Caron MG, Ellinwood EH. Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. Mol Pharmacol 1994;46:51-57.

199. Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 1989;243:398-400.

200. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-443.

201. Steketee JD, Striplin CD, Murray TF, Kalivas PW. Possible role for G-protein in behavioral sensitization to cocaine. Brain Res 1991;545:287.

202. Stevens JR. An anatomy of schizophrenia. Arch Gen Psychiatry 1973;29:177-189.

203. Stewart J, Vezina P. Conditioning and behavioral sensitization. In: Kalivas PW, Barnes CD, eds. Sensitization in the nervous system. Caldwell NJ: Telford Press, 1988;207.

204. Stripling JS, Ellinwood EH, Jr. Potentiation of the behavioral and convulsant effects of cocaine by chronic administration in the rat. Pharmacol Biochem Behav 1977;6:571-579.

205. Stunkard A, McLaren-Hume M. The results of treatment for obesity. Arch Intern Med 1959;1973103:79-85.

206. Sturner WQ, Spruill FG, Garriott JC. Two propylhexedrine-associated fatalities: benzedrine revisited. J Forens Sci 1974;19:572.

207. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995;15:4102-4108.

208. Sulzer D, Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 1990;5:797-808.

209. Tanda G, Frau R, Di Chiara G. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology 1996;127:83-87.

210. Tatetsu S. Methamphetamine psychosis. In: Ellinwood EH, Cohen S, eds. Current concepts on amphetamine abuse. DHEW Publication No. (HSM) 72-9085, Washington DC: US Gov't Printing Office, 1972;159-161.

211. Tatum AL, Seevers MH. Experimental cocaine addiction. J Pharmacol Exp Ther 1929;36:401-403.

212. Utena H, Machiyama Y, Hsu SC, Katagiri M, Hirata A. A monkey model for schizophrenia produced by methamphetamine. In: Kondo S, Kawai M, Ehara A, eds. Contemporary primatology. Basel: Karger, 1975;502-507.

213. Utena H. Behavioral aberrations in methamphetamine-intoxicated animals and chemical correlates in the brain. Prog Brain Res 1966;21B:192-207.

214. Vezina P. Amphetamine injected into the ventral tegmental area sensitizes the nucleus accumbens dopaminergic response to systemic amphetamine: an in vivo microdialysis study in the rat. Brain Res 1993;605:332-337.

215. Volkow ND, Hitzemann R, Wang GJ, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992;11:184-190.

216. Volkow ND, Mullani N, Gould KL, Alder S, Krajewski K. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry 1988;152:641-648.

217. Weddington W, Brown B, Haertzen C, et al. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. Arch Gen Psychiatry 1990;47:861-868.

218. Weihl WH. The effect of temperature on the action of drugs. In: Lomax P, Schonbaum E, eds. The pharmacology of thermoregulation. Basel: Karger, 1973;409-425.

219. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther. 1992;51:602-607.

220. Weiss F, Parsons LH, Makou A. Neurochemistry of cocaine withdrawal. In: Hammer R, ed. The neurobiology of cocaine. CRC Press. 1995;163-180.

221. Weiss B, Laites V. Effects of amphetamine, chlorpromazine and pentobarbital on behavioral thermoregulation. J Pharmacol Exp Ther 1963;140:1-7.

222. Wilbur DL, MacLean AR, Allen E. Clinical observations on the effect of benzedrine sulfate. JAMA 1937;109:549-554.

223. Wilens T, Biederman J. In: Pediatric psychopharmacology. The stimulants. 1992;191-222.

224. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med 1996;2:699-703.

225. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726.

226. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press, 1995.

227. Wise RA. The neurobiology of craving: Implications for understanding and treatment of addiction. J Abnorm Psychol 1988;97:118-132.

228. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 1989;486:73-78.

229. Yamada S, Yokoo H, Nishi S. Effects of N-ethylmaleimide on dopamine release in the rat striatum after repeated treatment with methamphetamine. Eur J Pharmacol 1994:257:243-248.

230. Yi SJ, Johnson KM. Chronic cocaine treatment impairs the regulation of synaptosomal (3H)-DA release by D2 autoreceptors. Pharmacol Biochem Beh 1990;36:457-461.

231. Young D, Scoville WB. Paranoid psychosis in narcolepsy and the possible danger of benzedrine treatment. Med Clin North Am 1938;197322:637-646.

232. Zahniser NR, Peris J. Neurochemical mechanisms of cocaine induced sensitization. In: Lakoski JM, Galloway MP, White FJ, eds. Cocaine: Pharmacology, physiology and clinical strategies. CRC Press, 1992;229-260.

233. Zalis EG, Parmley LF. Fatal amphetamine poisoning. Arch Intern Med 1963;112:822.

234. Zhang H, Lee TH, Ellinwood EH. The progressive changes of neuronal activities of the nigral dopaminergic neurons upon withdrawal from continuous infusion of cocaine. Brain Res 1992;594:315-318.

235 Zhong XH et al. Striatal tyrosine hydroxylase and dopa decarboxylase protein in dominantly-inherited olivopontocerebellar atrophy and idiopathic Parkinson's disease. Mov Disord 1995;10:10-17.